[Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer].

摘要: The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. first-in-class ALK tyrosine inhibitor, crizotinib, can effectively target these tumors represent a significant advance evolution personalized medicine for NSCLC. A randomized phase III clinical trial which superiority crizotinib over chemotherapy was seen previously treated ALK-positive NSCLC patients demonstrated durable responses and well tolerance majority with crizotinib. However, despite initial responses, most develop acquired resistance to Several novel therapeutic approaches targeting are currently under evaluation trials, including second-generation inhibitors, such as LDK378, CH5424802 (RO5424802), AP26113, new agents shock protein 90 inhibitors. This review aims present current knowledge on this fusion gene, treatment advances, drug trials rearranged